share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A:证券上市注册声明(修正)
美股SEC公告 ·  09/27 17:05

Moomoo AI 已提取核心信息

Heart Test Laboratories, Inc. (HeartSciences), a medical technology company, has announced a securities offering of up to 1,882,353 shares of its common stock. The offering is being managed by Maxim Group LLC as the exclusive placement agent. The company has also agreed to issue placement agent warrants for the purchase of up to 75,294 shares of common stock, with the warrants exercisable at 110% of the public offering price. The offering is being conducted on a best-efforts basis, with no minimum amount of securities required to be sold for the offering to proceed. The actual public offering price will be determined through negotiations between HeartSciences, the placement agent, and investors. The offering is subject to various terms and conditions as outlined in...Show More
Heart Test Laboratories, Inc. (HeartSciences), a medical technology company, has announced a securities offering of up to 1,882,353 shares of its common stock. The offering is being managed by Maxim Group LLC as the exclusive placement agent. The company has also agreed to issue placement agent warrants for the purchase of up to 75,294 shares of common stock, with the warrants exercisable at 110% of the public offering price. The offering is being conducted on a best-efforts basis, with no minimum amount of securities required to be sold for the offering to proceed. The actual public offering price will be determined through negotiations between HeartSciences, the placement agent, and investors. The offering is subject to various terms and conditions as outlined in a placement agency agreement and securities purchase agreements with investors. HeartSciences intends to use the net proceeds from the offering for FDA clearance-related costs, commercial development of licensed AI cardiovascular algorithms, research and development, working capital, and other general corporate purposes. The offering includes certain lock-up agreements restricting the issuance and sale of additional securities by the company and its officers and directors for specified periods post-offering. The common stock is listed on the Nasdaq Capital Market under the symbol 'HSCS'.
医疗技术公司Heart Test Laboratories, Inc.(HeartSciences)宣布将发行最多1,882,353股普通股的证券。该发行由Maxim Group LLC作为独家配售代理管理。公司还同意发行配售代理认股权证,购买最多75,294股普通股,认股权证行使价格为公开发行价格的110%。此次发行是在尽力而为的基础上进行的,无需销售最低的证券数量即可进行发行。实际的公开发行价格将通过HeartSciences、配售代理和投资者之间的协商确定。该发行受限于放置代理协议和与投资者签订的证券购买协议中概述的各种条款和条件。HeartSciences打算使用此次发行的净收入用于FDA核准相关成本、授权的人工智能心血管算法的商业开发、研发、营运资金和其他一般企业用途。该发行包括某些锁定协议,限制公司及其高管董事在发行后指定时期内发布和出售额外证券。这家普通股在纳斯达克资本市场上以“HSCS”标的进行交易。
医疗技术公司Heart Test Laboratories, Inc.(HeartSciences)宣布将发行最多1,882,353股普通股的证券。该发行由Maxim Group LLC作为独家配售代理管理。公司还同意发行配售代理认股权证,购买最多75,294股普通股,认股权证行使价格为公开发行价格的110%。此次发行是在尽力而为的基础上进行的,无需销售最低的证券数量即可进行发行。实际的公开发行价格将通过HeartSciences、配售代理和投资者之间的协商确定。该发行受限于放置代理协议和与投资者签订的证券购买协议中概述的各种条款和条件。HeartSciences打算使用此次发行的净收入用于FDA核准相关成本、授权的人工智能心血管算法的商业开发、研发、营运资金和其他一般企业用途。该发行包括某些锁定协议,限制公司及其高管董事在发行后指定时期内发布和出售额外证券。这家普通股在纳斯达克资本市场上以“HSCS”标的进行交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息